Measuring the Direct Medical Costs of Hospital-Onset Infections Using an Analogy Costing Framework.

IF 4.4 3区 医学 Q1 ECONOMICS PharmacoEconomics Pub Date : 2024-10-01 Epub Date: 2024-07-05 DOI:10.1007/s40273-024-01400-z
R Douglas Scott, Steven D Culler, James Baggs, Sujan C Reddy, Kara Jacobs Slifka, Shelley S Magill, Sophia V Kazakova, John A Jernigan, Richard E Nelson, Robert E Rosenman, Philip R Wandschneider
{"title":"Measuring the Direct Medical Costs of Hospital-Onset Infections Using an Analogy Costing Framework.","authors":"R Douglas Scott, Steven D Culler, James Baggs, Sujan C Reddy, Kara Jacobs Slifka, Shelley S Magill, Sophia V Kazakova, John A Jernigan, Richard E Nelson, Robert E Rosenman, Philip R Wandschneider","doi":"10.1007/s40273-024-01400-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The majority of recent estimates on the direct medical cost attributable to hospital-onset infections (HOIs) has focused on device- or procedure-associated HOIs. The attributable costs of HOIs that are not associated with device use or procedures have not been extensively studied.</p><p><strong>Objective: </strong>We developed simulation models of attributable cost for 16 HOIs and estimated the total direct medical cost, including nondevice-related HOIs in the USA for 2011 and 2015.</p><p><strong>Data and methods: </strong>We used total discharge costs associated with HOI-related hospitalization from the National Inpatient Sample and applied an analogy costing methodology to develop simulation models of the costs attributable to HOIs. The mean attributable cost estimate from the simulation analysis was then multiplied by previously published estimates of the number of HOIs for 2011 and 2015 to generate national estimates of direct medical costs.</p><p><strong>Results: </strong>After adjusting all estimates to 2017 US dollars, attributable cost estimates for select nondevice-related infections attributable cost estimates ranged from $7661 for ear, eye, nose, throat, and mouth (EENTM) infections to $27,709 for cardiovascular system infections in 2011; and from $8394 for EENTM to $26,445 for central nervous system infections in 2016 (based on 2015 incidence data). The national direct medical costs for all HOIs were $14.6 billion in 2011 and $12.1 billion in 2016. Nondevice- and nonprocedure-associated HOIs comprise approximately 26-28% of total HOI costs.</p><p><strong>Conclusion: </strong>Results suggest that nondevice- and nonprocedure-related HOIs result in considerable costs to the healthcare system.</p>","PeriodicalId":19807,"journal":{"name":"PharmacoEconomics","volume":null,"pages":null},"PeriodicalIF":4.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11405445/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40273-024-01400-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The majority of recent estimates on the direct medical cost attributable to hospital-onset infections (HOIs) has focused on device- or procedure-associated HOIs. The attributable costs of HOIs that are not associated with device use or procedures have not been extensively studied.

Objective: We developed simulation models of attributable cost for 16 HOIs and estimated the total direct medical cost, including nondevice-related HOIs in the USA for 2011 and 2015.

Data and methods: We used total discharge costs associated with HOI-related hospitalization from the National Inpatient Sample and applied an analogy costing methodology to develop simulation models of the costs attributable to HOIs. The mean attributable cost estimate from the simulation analysis was then multiplied by previously published estimates of the number of HOIs for 2011 and 2015 to generate national estimates of direct medical costs.

Results: After adjusting all estimates to 2017 US dollars, attributable cost estimates for select nondevice-related infections attributable cost estimates ranged from $7661 for ear, eye, nose, throat, and mouth (EENTM) infections to $27,709 for cardiovascular system infections in 2011; and from $8394 for EENTM to $26,445 for central nervous system infections in 2016 (based on 2015 incidence data). The national direct medical costs for all HOIs were $14.6 billion in 2011 and $12.1 billion in 2016. Nondevice- and nonprocedure-associated HOIs comprise approximately 26-28% of total HOI costs.

Conclusion: Results suggest that nondevice- and nonprocedure-related HOIs result in considerable costs to the healthcare system.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用类比成本计算框架衡量医院感染的直接医疗成本。
背景:最近对医院感染(HOIs)直接医疗成本的估算大多集中在与器械或手术相关的HOIs上。与器械使用或手术无关的医院感染的可归因成本尚未得到广泛研究:我们开发了 16 种急性呼吸道感染归因成本的模拟模型,并估算了 2011 年和 2015 年美国的直接医疗总成本,包括与设备无关的急性呼吸道感染:我们使用了全国住院病人样本中与心脑血管疾病相关的住院总出院成本,并采用类比成本计算方法建立了心脑血管疾病可归因成本的模拟模型。然后将模拟分析得出的平均归因成本估算值乘以之前公布的2011年和2015年HOI数量估算值,得出全国直接医疗成本估算值:将所有估算值调整为 2017 年美元后,2011 年特定非器械相关感染的归因成本估算值从耳眼鼻喉口腔感染的 7661 美元到心血管系统感染的 27709 美元不等;2016 年耳眼鼻喉口腔感染的归因成本估算值从 8394 美元到中枢神经系统感染的 26445 美元不等(基于 2015 年发病率数据)。2011 年全国所有 HOI 的直接医疗费用为 146 亿美元,2016 年为 121 亿美元。非器械和非手术相关 HOI 约占 HOI 总成本的 26-28%:结果表明,非器械和非手术相关的急性呼吸道感染给医疗系统带来了巨大的成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
PharmacoEconomics
PharmacoEconomics 医学-药学
CiteScore
8.10
自引率
9.10%
发文量
85
审稿时长
6-12 weeks
期刊介绍: PharmacoEconomics is the benchmark journal for peer-reviewed, authoritative and practical articles on the application of pharmacoeconomics and quality-of-life assessment to optimum drug therapy and health outcomes. An invaluable source of applied pharmacoeconomic original research and educational material for the healthcare decision maker. PharmacoEconomics is dedicated to the clear communication of complex pharmacoeconomic issues related to patient care and drug utilization. PharmacoEconomics offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article.
期刊最新文献
Design and Features of Pricing and Payment Schemes for Health Technologies: A Scoping Review and a Proposal for a Flexible Need-Driven Classification. Economic Burden Associated with Pulmonary Arterial Hypertension in the United States. The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis. Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability. How Much Better is Faster? Empirical Tests of QALY Assumptions in Health-Outcome Sequences.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1